Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia

Chimeric antigen receptor (CAR) T-cell therapy is transforming the landscape for treatment of B-lineage acute lymphoblastic leukemia (B-ALL). Chimeric antigen receptor T-cell therapy makes use of T cells that have been modified to target a cancer-specific cell surface antigen. There is currently 1 Food and Drug Administration–approved CD19-directed CAR T-cell therapy for relapsed/refractory B-ALL with numerous other CAR T-cell products under clinical investigation. This review covers the development of CAR T cells for B-ALL, citing the remarkable efficacy of inducing remissions in a very high-risk population of patients. However, following the first round of CAR T-cell trials targeting CD19 in B-ALL, it has been found that approximately 50% of patients who initially respond will ultimately recur. Current efforts in the field are focusing on the identification of targets beyond CD19 as well as advancing strategies to promote more durable remissions as work is ongoing to move this therapy upfront.
Source: The Cancer Journal - Category: Cancer & Oncology Tags: Review Articles Source Type: research

Related Links:

ConclusionThe findings indicate that 20(S)-GRh2 exhibits beneficial effects against T-ALL through the PI3K/Akt/mTOR pathway and could be a natural product of novel target for T-ALL therapy.
Source: Journal of Ginseng Research - Category: Complementary Medicine Source Type: research
In the original publication of this article [1], there is a mistake in Fig. 4E.
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Correction Source Type: research
Source: Clinical Nutrition - Category: Nutrition Authors: Tags: Nutrition and cancer II Source Type: research
Source: Clinical Nutrition - Category: Nutrition Authors: Tags: Nutritional techniques and formulations/Obesity and the metabolic syndrome/Nutrition and cancer/Nutritional assessment Source Type: research
Publication date: Available online 12 August 2019Source: Gynecologic Oncology ReportsAuthor(s): Jamil Kazma, Cynae Johnson, Nitin Jain, Vasantha Lakshmi Gali, Ken H. Young, Amir A. JazaeriAbstractThe involvement of the cervix as a site of relapse for hematologic malignancies is rare. We herein present a case of relapsed B-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL) mimicking advanced cervical cancer. The patient is a 61-year-old female with history B-cell ALL and had multiple relapses confined to the bone marrow and had received several different chemotherapy regimens. She presented with lower abdominal pain after the...
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conclusions: Maternal folic acid supplementation was found to have a protective effect against childhood acute lymphoblastic leukaemia. Thus, healthcare professionals are recommended to provide regular health education and health promotion to the community on the benefits of folic acid supplementation during pregnancy. PMID: 31396374 [PubMed - in process]
Source: Journal of Preventive Medicine and Public Health - Category: International Medicine & Public Health Tags: J Prev Med Public Health Source Type: research
Abstract CAR T cell therapy of cancers promises to revolutionize oncology by harnessing the powers of synthetic biology and immunotherapy in a single agent. CARs are synthetic receptors composed of an extracellular antigen binding domain and one or more intracellular signaling domains which act in concert to activate the T cell upon antigen recognition. CARs targeting B cell associated CD19 demonstrated robust in vivo cytolytic activity, expansion, and persistence upon antigen exposure paving the way for clinical application of this technology and ultimately FDA approval for pediatric and young adult acute lymphob...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Prog Mol Biol Transl Sci Source Type: research
ConclusionAsparaginase is a common cause of antineoplastic-induced liver injury with jaundice, typically with short latency, marked steatosis, and prolonged jaundice, which can lead to delays in antileukemic therapy. The cause of injury is likely direct inhibition of hepatic protein synthesis caused by asparagine depletion.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
MONDAY, Aug. 5, 2019 -- For Mexican children with acute lymphoblastic leukemia (ALL), overweight and obesity are predictors of early mortality, according to a study published online July 18 in BMC Cancer. Juan Carlos N úñez-Enríquez, M.D., from...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Leukemia